ZYUS Life Sciences Corporation announced receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human (?FIH?) Clinical Trial for its lead drug product candidate, Trichomylin® softgels.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.05 CAD | +3.96% | +5.00% | +16.67% |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 54.34M | |
+1.51% | 42.75B | |
+47.70% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ZYUS Stock
- News ZYUS Life Sciences Corporation
- ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels